Immunotherapy and its research progress of metastatic castration resistant prostate cancer / 中华泌尿外科杂志

The ideal immunotherapy should be highly lethal to the tumor and harmless to the body, therefore it’s applied to the highly fatal metastatic castration-resistant prostate cancer. Immunotherapy for prostate cancer currently includes vaccine therapy, immunocheckpoint blocking therapy, immunomodulator therapy, and combination therapy, which treat prostate cancer through different immune mechanisms. A vaccine called Sipuleucel-T has been approved by the Food and Drug Administration to treat metastatic castration-resistant prostate cancer, while research on other immune drugs is ongoing. This article reviews the current status and recent progress of various immunotherapies for metastatic castration-resistant prostate cancer.